On June 5, 2024, the Board of Directors of Allogene Therapeutics, Inc. appointed Annie Yoshiyama, the Company?s current Senior Vice President and Corporate Controller, as the Company?s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity. Mr. Parker continues to serve as the Company?s Chief Financial Officer and principal financial officer. Prior to joining the Company in April 2024, Ms. Yoshiyama, age 41, served as Vice President, Finance & Controller at AN2 Therapeutics, Inc. from September 2023 to March 2024; Senior Vice President Finance and Chief Accounting Officer, Vice President Finance and Chief Accounting Officer, Executive Director Finance, Senior Director Finance, Director SEC Reporting and Technical Accounting, and Associate Director SEC Reporting and Technical Accounting at Tricida, Inc. from June 2018 to March 2023; Senior Financial Reporting and Technical Accounting Manager at Dolby Laboratories from September 2008 to June 2018; and started her career in audit at PricewaterhouseCoopers LLP from September 2005 to August 2007.

Ms. Yoshiyama earned her Bachelor of Science and Master of Accounting degrees from the University of Southern California and is a licensed certified public accountant.